Prodromal Lewy body disorder features in REM sleep behavior disorder with biomarker-defined synucleinopathy

Daniel Weintraub, MD;[1] Michele K. York, PhD;[2] Roseanne Dobkin, PhD;[3] Anuprita R Nair, MPH;[4] Ryan Kurth, MS;[4] David-Erick Lafontant, PhD;[4] Chelsea Caspell-Garcia, MS;[4] Roy N. Alcalay, MD;[5] Ethan G. Brown, MD;[6] Lana M. Chahine, MD;[7] Christopher Coffey, PhD;[4] Tatiana Foroud, PhD;[8] Douglas Galasko, MD;[9] Karl Kieburtz, MD;[10] Kenneth Marek, MD;[11] Kalpana Merchant, PhD;[12] Brit Mollenhauer, MD;[13] Kathleen L. Poston, MD;[14] Andrew Siderowf, MD;[1] Cristina Simonet;[15] Tanya Simuni, MD;[12] Caroline M. Tanner, MD, PhD;[6] Thomas F. Tropea, DO;[11] Aleksandar Videnovic, MD;[16] and the Parkinson's Progression Markers Initiative*

***See Supplementary File 1**

Author Affiliations:

1. Departments of Psychiatry and Neurology, Pearlman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
2. Department of Neurology, Baylor College of Medicine; Houston, TX 77030, USA
3. Department of Psychiatry, Rutgers University; New Brunswick, NJ 08901, USA
4. Department of Biostatistics, University of Iowa; Iowa City, IA 52246, USA
5. Movement Disorders Division, Tel Aviv Sourasky Medical Center; Tel Aviv, Israel; Columbia University Irving Medical Center, New York, NY
6. Department of Neurology, University of California San Francisco; San Francisco, CA 94143, USA
7. Department of Neurology, University of Pittsburgh; Pittsburgh, PA 15213, USA
8. Department of Medical and Molecular Genetics, Indiana University; Indianapolis, IN 46202, USA
9. Department of Neurosciences, University of California; San Diego, CA 92093, USA
10. Department of Neurology, University of Rochester; Rochester, NY 14618, USA
11. Institute for Neurodegenerative Disorders, New Haven, CT 06510, USA
12. Department of Neurology, Northwestern University; Chicago, IL 60611, USA

13. Department of Neurology, University Medical Center Göttingen, Göttingen, Germany and Paracelsus-Elena Klinik, Kassel, Germany
14. Department of Neurology, Stanford University; Stanford, CA 94305, USA
15. Centre for Preventive Neurology, Wolfson Institute for Population Health; Queen Mary University of London, London, England
16. Division of Sleep Neurology, Massachusetts General Hospital; Boston, MA 02114, USA

Correspondence to:
Daniel Weintraub
3615 Chestnut St., Philadelphia, PA19104
daniel.weintraub@pennmedicine.upenn.edu

Title: 107 characters
Running head: 31 characters
Word counts
Abstract: 246
Introduction: 456
Discussion: 781
Body: 3103
Figures: 2
Tables: 3

ABSTRACT

Objective: Isolated rapid eye movement sleep behavior disorder (iRBD) is a prodromal state for Lewy body disorders and exhibits biological heterogeneity that may influence clinical expression and progression. We examined clinical features in individuals with iRBD and biomarker-defined synucleinopathy.

Methods: Parkinson's Progression Markers Initiative (PPMI) is a longitudinal, multi-center observational study. Participants included polysomnogram (PSG)-confirmed iRBD individuals who were cerebrospinal fluid (CSF) α-synuclein seed amplification assay positive with no clinical diagnosis of Parkinson's disease or dementia with Lewy bodies, along with robust healthy controls (HCs). Clinical and biological features of prodromal PD and DLB, including mild cognitive impairment (MCI), subthreshold parkinsonism, and a range of neuropsychiatric, autonomic and sensory symptoms, were assessed.

Results: Compared with HCs (N=136), iRBD participants (N=197) demonstrated worse cognitive performance, including a lower cognitive summary score (p<0.0003, effect size = 0.41), and higher odds of subthreshold parkinsonism (OR = 24.5), and neuropsychiatric (OR = 3.5), autonomic (OR = 7.2) and sensory symptoms (OR = 13.2). Common features included hyposmia (75%), pain (54%), urinary problems (52%), constipation (49%), lightheadedness (40%) and anxiety (36%), whereas rates of MCI (32%), subthreshold parkinsonism (27%) and psychosis (7%) were lower. iRBD participants with abnormal dopamine transporter imaging had higher anxiety scores and antidepressant use. Although only 10% met criteria for prodromal DLB due to the requirement for MCI, most exhibited multi-domain impairment.

Interpretation: iRBD with synucleinopathy is associated with multi-domain clinical impairment prior to clinical neurodegenerative disease diagnosis, supporting broad clinical assessment in early biomarker-defined synuclein disease.

INTRODUCTION

Rapid eye movement sleep behavior disorder (RBD) is present in up to 75% of Parkinson's disease (PD) and 90% of dementia with Lewy body (DLB) patients long-term.[1] In DLB, RBD is considered a core clinical feature,[2] and in PD, RBD symptoms are associated with faster cognitive decline[3] and increased risk for dementia.[4]

Isolated RBD (iRBD) has emerged as the prodromal feature with the highest specificity for future risk of diagnosis of a Lewy body disorder (LBD; i.e., synucleinopathy, either PD or DLB), with an overall conversion rate from iRBD to an overt neurodegenerative syndrome of approximately 75% over 10 or more years.[5,6] Over the past decade, research diagnostic criteria for both prodromal PD[7,8] and DLB[9] have been proposed, and iRBD is prominent in both sets of criteria. In addition to a focus on iRBD, cognition,[10-12] and parkinsonism,[13] these criteria also incorporate psychiatric,[14,15] autonomic,[16,17] and sensory[15,18] symptoms, which occur more frequently in these populations compared with controls and predict progression to a clinically-defined synucleinopathy.[11,15,16,18-20]

For RBD pathophysiology, clinical and basic science suggest that α-synuclein pathology begins in the lower brainstem where REM atonia circuits are located, then propagates rostrally to brain regions such as the substantia nigra, limbic system, and cortex. Regarding presence of biologically-defined neuronal synuclein disease (NSD), in one study 85% of participants with iRBD had a positive cerebrospinal fluid [CSF] α-synuclein seed amplification assay [SAA] test,[21] suggesting that detectable synuclein disease occurs prior to onset of significant clinical symptoms that would lead to a LBD diagnosis. Another biological marker of synuclein disease is dopaminergic dysfunction, often measured by dopamine transporter (DAT) SPECT imaging (e.g., DaTscan). In PD, mean striatal DAT SBR is inversely correlated with increasing RBD symptom score,[22] and the mean striatal SBR value decreases more over time in patients with RBD symptoms.[23]

The Parkinson's Progression Markers Initiative (PPMI) is a prospective cohort study that enrolls participants with prodromal PD, including iRBD. In that cohort, progression to a clinical

synucleinopathy is associated with olfaction, depression, cognition, CSF ptau:total tau ratio, cortical atrophy, and dopamine transporter (DAT) SPECT imaging binding.[24,25]

There is considerable heterogeneity in the pathophysiology of iRBD, and to date, no studies have focused only on individuals with *in vivo* characterization of synucleinopathy, who would be presumed to have the highest risk and earliest likelihood of conversion to a clinically-diagnosed synuclein neurodegenerative disorder. In this context, we present the clinical and biological characteristics of a multi-center, international cohort of individuals with PSG-confirmed iRBD and biologically-defined synucleinopathy, including presence of symptoms across multiple clinical domains reported to be affected in prodromal PD and DLB. We hypothesized that iRBD patients would be more likely to have a wide range of symptoms across multiple clinical domains, and in varying combinations, compared with robust healthy controls.

METHODS

Cohorts

Isolated RBD (N=197)

Data for this analysis were from the PPMI, an international, multicenter, prospective, cohort study.[26] The iRBD cohort were: (1) enrolled into PPMI study post-2020; (2) PSG-confirmed RBD; (3) NSD positive at baseline based on positive CSF α-synuclein SAA test (Type 1, neuronal type; see below); (4) without a local site investigator (LSI) diagnosis of PD, dementia or other neurodegenerative disease at baseline; (5) not on any PD meds; and (6) without GBA1 Gaucher-causing variants.

Robust healthy controls (N=136)

The robust healthy controls (HCs) were a subset of PPMI participants previously described.[27,28] They were: (1) enrolled into the PPMI study as a HC at any time point; (2) excluded for having possible iRBD, defined by a score ≥ 6 on the RBDSQ, self-reporting an RBD diagnosis without PSG confirmation, or self-reporting dream enactment behavior; (3) NSD negative based on CSF α-synuclein SAA tests, with any longitudinal SAA test negative too; and (4) DaTscan negative.

Variables

Demographic

Demographic variables were biological sex, age at baseline visit, race, ethnicity, and number of years of formal education.

NSD-ISS

iRBD participants were assigned to a Neuronal alpha-Synuclein Disease Integrated Staging System (NSD-ISS) stage as previously described.[29,30] Of relevance to this paper, Stage 2 is subtle functional impairment on the basis of motor, cognitive or other non-motor symptoms; Stage 3 is slight impairment on the basis of motor or cognitive symptoms; and Stage 4 is mild impairment on the basis of motor, cognitive or other non-motor symptoms.

Cognitive

The LSI completed a clinical features checklist including a single item about presence of cognitive fluctuations (yes/no) and assigned a cognitive diagnosis (normal cognition, mild cognitive impairment [MCI] or dementia) at the baseline visit.[31] Other variables were Montreal Cognitive Assessment (MoCA) score[32] and a recently-developed and -utilized PPMI cognitive summary score (CSS) that is age- and sex-adjusted.[27,28] For the scope of this study, MCI was defined as a MoCA score ≤ 25[33] to be most consistent with rates of MCI reported in other iRBD cohorts, as a well-accepted cut-off for MCI,[33] and as most likely to have clinical applicability (**Supplementary Table 1**).

Motor

Motor variables were MDS-UPDRS Part II total score and Part III total scores. In addition, subthreshold parkinsonism, the motor anchor for Stage 2 (i.e., subtle symptoms) in NSD-ISS, was defined as an MDS-UPDRS Part III score ≥ 5, excluding the postural and action tremor items.[30]

Neuropsychiatric

Neuropsychiatric variables were: (1) 15-item Geriatric Depression Scale (GDS-15)[34]; (2) State subscale of the State-Trait Anxiety Inventory (STAI)[35]; (3) MDS-UPDRS Part I Hallucination and Psychosis item score; and (4) MDS-UPDRS Part I Apathy item score. In addition, the use

(yes/no) of three neuropsychiatric medication classes were recorded: benzodiazepine, antidepressant, and iRBD treatment (either clonazepam or melatonin).

Autonomic

Autonomic symptoms were presence of MDS-UPDRS Part I Urinary Problems score ≥ 1, Lightheadedness on Standing score ≥ 1, and Constipation Problems score ≥ 1.

Sensory

Sensory symptoms were presence of hyposmia (UPSIT score ≤ 15th percentile) and MDS-UPDRS Part I Pain and Other Sensations score ≥ 1.

Prodromal DLB criteria

As all individuals in the PSG-confirmed iRBD cohort had a confirmed proposed biomarker for prodromal DLB, only one additional core clinical feature beyond the essential criterion of MCI was needed.[7] The core clinical features are fluctuating cognition, recurrent visual hallucinations, and parkinsonism; iRBD was not allowed to count as a core clinical feature as it was already an inclusion criterion for these analyses. MCI was diagnosed by MoCA score ≤ 25, presence of fluctuating cognition was a "yes" response by the LSI to the "cognitive fluctuations" question, recurrent visual hallucinations was MDS-UPDRS Part I Hallucination and Psychosis item score ≥ 1, and parkinsonism was at least "subthreshold" based on an MDS-UPDRS Part III Motor Examination score ≥ 5 (excluding postural or action tremor).

Neurobiological

Neurobiological variables were: (1) Amprion CSF neuronal α-synuclein SAA test results for determining presence of NSD[21]; (2) DaTscan results, reported as the mean striatal SBR and as dopaminergic dysfunction based on lowest putamen value < 75th percentile SBR applying age- and sex-adjusted norms[26]; and (3) University of Pennsylvania Smell Identification Test (UPSIT) to assess olfaction.[36] Hyposmia was defined as ≤ 15th percentile applying age- and sex-adjusted norms for the revised UPSIT.[37,38]

Statistics

Descriptive statistics at baseline were presented for iRBD participants and the robust HC group, including frequencies (percentages) for categorical measures, and means and standard deviations (SDs) or medians and interquartile ranges (IQRs) for continuous measures. Age- and sex-adjusted statistical comparisons of characteristics between the two groups were performed using logistic regression models for categorical measures, and general linear regression models for continuous measures. The Benjamini & Hochberg method was used to control the false discovery rate at 5%.

Descriptive statistics were also presented separately for the DaTscan-normal iRBD participants, DaTscan-abnormal iRBD participants, and robust HCs. Pairwise comparisons were performed between DAT-abnormal and DAT-normal iRBD participants using Wilcoxon rank sum tests for continuous measures, and Chi-square or Fisher's exact test as appropriate for categorical measures. For comparisons between robust HCs, DAT-abnormal iRBD, and DAT-normal iRBD participants respectively, logistic regression models were used for categorical measures, and general linear regression models were used for continuous measures. These were adjusted for age and sex. Again, the Benjamini & Hochberg method was used to control the false discovery rate at 5%.

Criteria for probable prodromal DLB were evaluated for the overall iRBD cohort and were also reported by DaTscan status. The frequencies and percentages of participants who met each criterion were reported. MCI definitions were assessed by reporting their frequencies (percentages) across the iRBD NSD cohort.

The comorbid clinical symptoms of prodromal DLB among iRBD participants were assessed across five core clinical domains, and the frequency (percentage) of participants meeting the criteria for each was reported. An UpSet plot was used to display the percentage of participants with different combinations of comorbid clinical symptoms in the iRBD cohort. Prodromal LBD categories were reported based on the number of domains for which they met the criteria. The percentage of each clinical feature within each category was plotted on a cluster bar graph for participants with iRBD and one to four additional core clinical feature domains. The above analysis was repeated by applying more stringent criteria for defining the core clinical feature

domains (i.e., for MDS-UPDRS Part I items having a score ≥ 2 for presence of the symptom). Odds ratios and 95% confidence intervals were reported for comparisons of the LBD symptoms between the iRBD group and the robust HC group.

Statistical analyses were performed using SAS v9.4 (SAS Institute Inc., Cary, NC; sas.com; RRID:SCR_008567). UpSet plots and bar charts were created using the "ComplexUpset" package in R Statistical Software (v 4.4.1; R Core Team 2025).

RESULTS

Characteristics of cohorts

Demographics

197 iRBD and 136 robust HC participants were included. iRBD participants were more likely to be male, white, Hispanic, and older, with a similar education level **(Table 1)**. There were 4 iRBD and 5 robust HC participants who had the non-Gaucher causing GBA1 genetic variants.

NSD-ISS staging of iRBD participants

Approximately half (49%) were DaTscan abnormal (**Table 2**). Most (87%) iRBD participants were NSD-ISS Stage 2 at study enrollment; approximately 15% of participants were either Stage 3 (4%) or Stage 4 (10%). Of the 26 participants that were Stages 3 or 4, 16 met non-motor criteria, 10 cognitive criteria, and 4 motor criteria (4 participants met multiple criteria) (**Supplementary Table 2**).

Clinical characteristics

The median duration of iRBD diagnosis was approximately two years, with median duration of symptoms being approximately six years (**Table 1**).

MoCA scores were approximately two points lower in the iRBD group. Nevertheless, their mean score remained within the unimpaired range, and only 16% of participants were diagnosed with MCI by the site investigator. The CSS was significantly lower in the iRBD group (*z*-score difference = 0.27, *p*-value = 0.0003, effect size = 0.41).

Motor scores (MDS-UPDRS Parts II and III) were higher in iRBD than in HCs but were low overall.

The iRBD group had higher depression and anxiety scores on disorder-specific rating scales than did the HC group, and using the cut-off scores on the MDS-UPDRS Part I had higher rates of psychosis and apathy. Applying cut-off scores to all neuropsychiatric symptoms within the iRBD group, the rates of depression, anxiety, and apathy were all higher than psychosis.

There was a strong association between iRBD status and olfaction, with 75% of iRBD participants having hyposmia versus 6% of HCs.

Approximately 2/3 of iRBD participants were taking a medication for their sleep disorder, and 1/4 were on an antidepressant. We found no association between sleep medication use and either the MoCA (*p*-value = 0.6946) or the CSS (*p*-value = 0.2411).

Impact of dopamine system dysfunction in iRBD participants

Demographic characteristics and iRBD duration were similar for Stages 2A and 2B participants (**Table 2**). There was no impact of an abnormal DaTscan on cognitive performance as assessed with the MoCA, CSS, or LSI cognitive diagnosis. Likewise, there were no between-group differences in motor scores. For neuropsychiatric symptoms, anxiety scores were higher in those iRBD participants with an abnormal DaTscan. Antidepressant use was more prevalent in Stage 2B.

Criteria for probable prodromal Lewy body dementia

After applying the prodromal DLB criteria,[9] only 10% of iRBD participants met the criteria (**Supplementary Table 3**). Even though approximately one-third (32%) of iRBD participants met the criterion for MCI, only 27% of the entire cohort met the criterion for subthreshold parkinsonism, 7% for psychosis, and 2% for fluctuating cognition. The results were similar for those in Stage 2A versus 2B.

Prevalence of symptoms across five clinical domains in iRBD

By moving beyond existing diagnostic criteria and evaluating symptoms across a broader range of clinical domains known to be affected in prodromal Lewy body disease, we found that individuals with iRBD exhibit a diverse spectrum of impairments.

Applying less stringent cut-offs for MDS-UPDRS items (i.e., score ≥ 1 for presence of symptom), rates of any sensory symptom, any autonomic symptom, and any neuropsychiatric symptom all exceeded 50%, higher than rates for MCI or subthreshold parkinsonism (**Table 3, Figure 1**).

Applying more stringent cut-offs for MDS-UPDRS items, rates of sensory impairment remained very high (due to the criterion for hyposmia being unchanged), and autonomic and neuropsychiatric symptoms were of comparable prevalence to MCI and parkinsonism (**Supplementary Table 4**, **Supplementary Figure 1**).

Figure 2 is an UpSet plot based on less stringent MDS-UPDRS cut-offs, and there were nine additional symptoms or combination of symptoms with ≥ 5% prevalence, together representing 79% of the entire cohort. **Supplementary Figure 2** is an UpSet plot based on more stringent MDS-UPDRS cut-offs.

Odds of domain impairment in iRBD versus healthy controls

Symptoms in all four non-cognitive domains were significantly more common in the iRBD cohort compared with HCs, regardless of less or more stringent MDS-UPDRS cut-offs being applied (**Supplementary Table 5**). Although the prevalence of sensory, autonomic, and neuropsychiatric symptoms decreased among iRBD participants when more stringent cut-offs were applied, the odds ratios for the prevalence of these symptoms in iRBD compared with HCs increased. The highest odds ratios were for parkinsonism and sensory symptoms. We reran the odds ratios for iRBD versus HCs adjusting for age and sex, and the results were similar (**Supplementary Table 6**).

DISCUSSION

In a multi-center, international cohort, participants with iRBD and *in vivo* biomarker-defined synucleinopathy, but without a clinically-diagnosed neurodegenerative disease, demonstrated poorer performance than a robust healthy control group across multiple clinical domains, including cognitive, motor, neuropsychiatric, autonomic, and sensory. Typically, multiple-domain impairment combinations were observed. Clinical associations of dopaminergic deficiency as an additional biological feature were observed, notably greater neuropsychiatric comorbidity, but not parkinsonism or cognition. The most common individual symptoms or features in the iRBD group were hyposmia, pain and other sensations, urinary dysfunction, constipation, lightheadedness on standing, and anxiety, whereas the core clinical features of LBDs, parkinsonism, and cognitive impairment were less common. Importantly for clinical research, we also found that existing research diagnostic criteria for prodromal LBDs[9] may be too restrictive or fail to capture certain symptoms that are commonly observed in the early stage of synuclein disease.

Our results indicate that cognitive deficits are present in iRBD regardless of dopaminergic deficit. This suggests that the neurobiological basis for early cognitive decline in this population is in part non-dopaminergic and non-striatal, consistent with cholinergic[39] and noradrenergic[40,41] deficits present in iRBD, as well as Lewy body pathology observed postmortem in extra-striatal regions (e.g., brainstem, limbic system), even in individuals without a neurodegenerative disease diagnosis.[42] We found that having a positive DaTscan was associated with higher anxiety scores and antidepressant use, which is consistent with previous research showing a role for the dopamine system in affective symptoms in PD,[43] or perhaps reflecting the involvement of other brainstem nuclei (e.g., raphe) associated with affective symptoms.[44,45]

One objective of our research was to determine how many iRBD participants met the research diagnostic criteria for prodromal DLB.[9] Regarding the essential clinical feature of MCI, we found that approximately 1/3 of iRBD participants met the criterion based on the MoCA cut-off score and that their impairment on the CSS was of a medium effect size, which is consistent with previous research findings of high rates of cognitive deficits in iRBD.[10,11] However, the other core clinical features were uncommon. Thus, formal prodromal DLB criteria was met in only

10% of iRBD participants, indicating that this prodromal syndrome, as currently defined, is uncommon in recently-diagnosed iRBD.

Moving beyond existing diagnostic criteria revealed a substantially more complex symptom profile. All five clinical domains examined were more impaired in iRBD than in the robust HC group, with the highest rate found for the sensory domain due to almost 75% of iRBD participants having hyposmia, which has been reported to be more common in iRBD than in healthy controls.[18] In addition, persons with comorbid iRBD and hyposmia have been reported to have elevated rates of cognitive deficits, motor symptoms, depression, and apathy.[46] In addition, elevated rates of neuropsychiatric[47] and autonomic[48] symptoms have also been demonstrated in iRBD.

Following hyposmia, the most frequently-reported symptoms included another sensory symptom (pain), autonomic symptoms such as urinary dysfunction, constipation, and lightheadedness, as well as neuropsychiatric symptoms, primarily anxiety. In contrast, the diagnostic signs and symptoms of PD (motor) and DLB (dementia) were less prevalent, as were fluctuating cognition and psychosis. We also found that multi-clinical domain impairment was common, and in many combinations. This significant co-morbidity was despite the median duration of iRBD being only two years, which is notably shorter at study entry than previously-reported cohorts.[49-51]

Limitations of the research worth noting are having only single items for certain symptoms (e.g., cognitive fluctuations, apathy and psychosis), defining MCI on the basis of a MoCA cut-off score, and the presence of demographic differences (i.e., age, sex, race and ethnicity) between the iRBD and HC groups. Regarding the latter point, the odds ratios for frequency of clinical domains affected in the iRBD versus the HC groups were similar when adjusted for age and sex, and the cognitive summary score utilized is age- and sex-corrected. Also, we chose to focus only on probable DLB criteria, not possible DLB. In addition, we chose to focus on iRBD participants who had biomarker-defined synucleinopathy, so we did not compare those iRBD participants who are α-synuclein SAA+ versus those who are SAA-, which can be done in future studies.

Although PD and DLB are diagnosed by the presence of parkinsonism and dementia, our results show that in iRBD with biologically-defined synucleinopathy, clinical features in other domains (i.e., neuropsychiatric, autonomic, and sensory) are equally or more prevalent, suggesting that widespread synuclein pathology is present even in recently-diagnosed iRBD. Moreover, symptoms across all clinical domains occur far more frequently in iRBD than in healthy controls and co-occur in diverse combinations. These findings highlight the importance of assessing multiple clinical domains in early or prodromal synuclein disease rather than anchoring diagnostic criteria or assessment instruments solely to motor symptoms or cognitive impairment.

ACKNOWLEDGEMENTS

PPMI – a public-private partnership – is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including 4D Pharma, Abbvie, AcureX, Allergan, Amathus Therapeutics, Aligning Science Across Parkinson's, AskBio, Avid Radiopharmaceuticals, BIAL, BioArctic, Biogen, Biohaven, BioLegend, BlueRock Therapeutics, Bristol-Myers Squibb, Calico Labs, Capsida Biotherapeutics, Celgene, Cerevel Therapeutics, Coave Therapeutics, DaCapo Brainscience, Denali, Edmond J. Safra Foundation, Eli Lilly, Gain Therapeutics, GE HealthCare, Genentech, GSK, Golub Capital, Handl Therapeutics, Insitro, Jazz Pharmaceuticals, Johnson & Johnson Innovative Medicine, Lundbeck, Merck, Meso Scale Discovery, Mission Therapeutics, Neurocrine Biosciences, Neuron23, Neuropore, Pfizer, Piramal, Prevail Therapeutics, Roche, Sanofi, Servier, Sun Pharma Advanced Research Company, Takeda, Teva, UCB, Vanqua Bio, Verily, Voyager Therapeutics, the Weston Family Foundation and Yumanity Therapeutics.

AUTHOR CONTRIBUTIONS

Conception and design of the study: (author initials)
Acquisition and analysis of data:
Drafting of the manuscript and figures:
Contributions from the PPMI study group can be found in **Supplementary File 1.**

CONFLICTS OF INTEREST

The authors report no competing interests.

DATA AVAILABILITY

Data used in the preparation of this article were obtained on Jan 21, 2025, from the Parkinson's Progression Markers Initiative (PPMI) database (www.ppmi-info.org/access-data-specimens/download-data), RRID:SCR_-006431. For up-to-date information on the study, visit www.ppmi-info.org.

This analysis was conducted by the PPMI Statistics Core and used actual dates of activity for participants, a restricted data element not available to public users of PPMI data. This analysis

used DAT-SPECT and aSynSAA results for participants of the Prodromal Cohort, obtained from PPMI upon request after approval by the PPMI Data Access Committee.

Protocol information for The Parkinson's Progression Markers Initiative (PPMI) Clinical - Establishing a Deeply Phenotyped PD Cohort AM 3.2. can be found on protocols.io or by following this link: https://dx.doi.org/10.17504/protocols.io.n92ldmw6ol5b/v2.

Statistical analysis codes used to perform the analyses in this article are shared on Zenodo [10.5281/zenodo.17611026].

FIGURE LEGENDS

Figure 1. Bar graphs of frequency of comorbid clinical domains in iRBD using original criteria

Figure 2. UpSet plot of overlap of comorbid clinical features

Table 1. Characteristics of all NSD positive iRBD and robust HC participants

Variables	Group Robust HCs (NSD-, DaTscan-) (N=136)	PSG-confirmed iRBD (NSD+, DaTscan +/-) (N=197)	p-value ****
DEMOGRAPHICS			
Sex (male), N (%)	84 (62%)	156 (79%)	0.0005 ^
Age at baseline, Mean (SD) years	59.7 (11.6)	68.2 (6.1)	<.0001 ^
Race (white), N (%)	123 (90%)	187 (96%) *	0.5970
Ethnicity (Not Hispanic), N (%)	134 (99%)	179 (94%) *	0.0538
Education, Mean (SD) years	16.2 (2.7)	16.1 (3.2)	0.1697
NSD-ISS STAGE *			
Stage 1	0 (0%)	0 (0%)	-
Stage 2	0 (0%)	170 (87%)	
Stage 3	0 (0%)	7 (4%)	
Stage 4	0 (0%)	19 (10%)	
Not NSD	130 (100%)	0 (0%)	
Missing	6	1	
CLINICAL CHARACTERISTICS			
Duration RBD diagnosis (years), Median (Min, Max) **	N/A	2.2 (0.2, 30.1) *	-
Duration RBD symptoms (years), Median (Min, Max) ***	N/A	6.2 (1.0, 48.4) *	-
MoCA, Mean (SD)	28.3 (1.1)	26.5 (2.5)	-
Site investigator diagnosis of MCI, N (%)	- *	32 (16%)	0.0328 ^
Cognitive Summary Score, Mean (SD)	-0.06 (0.63)	-0.33 (0.68)	0.0003 ^
GDS-15 score, Mean (SD)	1.2 (2.2)	2.1 (2.2)	0.0005 ^
STAI-State score, Mean (SD)	26.1 (6.1)	30.8 (9.8)	<.0001 ^
MDS-UPDRS Part I Psychosis Score, N (%) *			0.0082 ^
Normal	135 (100%)	183 (93%)	
Slight	0 (0%)	12 (6%)	
Mild	0 (0%)	1 (1%)	
MDS-UPDRS Part I Apathy Score, N (%) *			0.0002 ^
Normal	131 (97%)	155 (79%)	
Slight	4 (3%)	23 (12%)	
Mild	0 (0%)	16 (8%)	
Moderate	0 (0%)	2 (1%)	
MDS-UPDRS Part II score, Mean (SD)	0.3 (0.9) *	2.2 (3.3)	<.0001 ^
MDS-UPDRS Part III score, Mean (SD)	0.9 (1.4) *	4.4 (4.7) *	<.0001 ^
Benzodiazepine use (yes), N (%)	5 (4%)	6 (3%)	0.9072
Antidepressant use (yes), N (%)	14 (10%)	50 (25%)	0.0001 ^
RBD treatment (yes), N (%)	7 (5%)	124 (63%)	<.0001 ^
BIOLOGIC CHARACTERISTICS			
CSF αSyn-SAA (positive), N%	0 (0%)	197 (100%)	-
DaTscan mean striatal SBR, Mean (SD)	2.69 (0.53) *	2.02 (0.54)	<.0001 ^
DaTscan (lowest putamen <75% SBR), N (%)	0 (0%) *	96 (49%)	-
UPSIT (raw score), Mean (SD)	34.6 (3.8)	21.4 (6.8)	<.0001 ^
Hyposmia (% ≤ 15th percentile), N (%)	8 (6%)	147 (75%)	<.0001 ^

* 2 iRBD participants had missing race information and 6 iRBD participants had missing ethnicity information. Stage was missing for 6 robust HCs and 1 iRBD participant. Duration of self-reported time since RBD diagnosis and duration of self-reported time since RBD symptoms onset was missing for 9 iRBD participants. 3 iRBD participants with duration of self-reported time since RBD symptom onset were excluded due to implausible values (onset of symptoms < 21 years of age). Site investigator cognitive diagnosis was not reported for robust HC group since it was missing for 85 HCs and only 1 HC participant had MCI diagnosis. MDS UPDRS Part 1 Psychosis and Apathy scores were missing for 1 robust HC and 1 iRBD participant. MDS-UPDRS Part II and Part III score were missing for 1 robust HC participant, while 3 iRBD participants had a missing Part III score. Mean striatum and lowest putamen score categorical variable was missing for 4 robust HC participants due to missing DaTscan.

** Duration of self-reported time since RBD diagnosis in years.

*** Duration of self-reported time since onset of RBD symptoms in years.

**** Comparison between iRBD and robust HC group was adjusted for age and sex and performed using linear regression models for continuous variables, and logistic regression models for categorical variables. The comparisons between the two groups for age, sex, cognitive composite score and hyposmia (% < 15th percentile) was not adjusted for age and sex and performed using Wilcoxon-rank sum tests for continuous variables, and Chi-square tests for categorical variables.

^ The Benjamini & Hochberg method was used to control the false discovery rate at 5%. The upper BH boundary was 0.0395; therefore, all p-values less than 0.0395 are considered significant (indicated by the '^' at the end of the p-value)..

Table 2. Characteristics of DAT positive iRBD, DAT negative iRBD and robust HC participants

	Group			p-values ****		
Variables	**Robust HCs (NSD-, DaTscan-)** (N =136)	**PSG-confirmed iRBD (NSD+, DaTscan-; 2A)** (N=101)	**PSG-confirmed iRBD (NSD+, DaTscan+; 2B-4)** (N=96)	**p-value (HC vs 2A)**	**p-value (HC vs 2B-4)**	**p-value (2A vs 2B-4)**
DEMOGRAPHICS						
Sex (male), N (%)	84 (62%)	78 (77%)	78 (81%)	0.0114 ^	0.0014 ^	0.4870
Age at baseline, Mean (SD) years	59.7 (11.6)	68.0 (6.2)	68.5 (6.0)	<.0001 ^	<.0001 ^	0.5658
Race (white), N (%)	123 (90%)	93 (94%) *	94 (98%)	0.9084	0.2091	0.2793
Ethnicity (Not Hispanic), N (%)	134 (99%)	89 (93%) *	90 (95%) *	0.0385	0.1513	0.5635
Education, Mean (SD) years	16.2 (2.7)	15.7 (3.4)	16.5 (2.9)	0.0607	0.7790	0.1500
CLINICAL CHARACTERISTICS						
Duration RBD diagnosis (years), Mean (SD) **	-	3.3 (3.8) *	3.6 (4.9) *	-	-	0.9211
Duration RBD symptoms (years), Mean (SD) ***	-	9.0 (9.3) *	10.1 (10.3) *	-	-	0.7455
MoCA, Mean (SD)	28.3 (1.1)	26.3 (2.5)	26.7 (2.5)	-	-	0.2784
Cognitive Summary Score, Mean (SD)	-0.06 (0.63)	-0.30 (0.69)	-0.37 (0.68)	0.0060 ^	0.0005 ^	0.4936
Site investigator diagnosis of MCI, N (%)	- *	15 (15%)	17 (18%)	0.0443	0.0314	0.5869
GDS-15 score, Mean (SD)	1.2 (2.2)	2.0 (2.2)	2.2 (2.2)	0.0101 ^	0.0008 ^	0.4223
STAI-State score, Mean (SD)	26.1 (6.1)	28.7 (8.5)	33.0 (10.6)	0.0078 ^	<.0001 ^	0.0053 ^
MDS-UPDRS Part I Psychosis Score, N (%) *				0.0185 ^	0.0109 ^	0.6881
Normal	135 (100%)	95 (94%)	88 (93%)			
Slight	0 (0%)	5 (5%)	7 (7%)			
Mild	0 (0%)	1 (1%)	0 (0%)			
MDS-UPDRS Part I Apathy Score, N (%) *				0.0023 ^	<.0001 ^	0.1490
Normal	131 (97%)	84 (83%)	71 (75%)			
Slight	4 (3%)	8 (8%)	15 (16%)			
Mild	0 (0%)	7 (7%)	9 (9%)			
Moderate	0 (0%)	2 (2%)	0 (0%)			
MDS-UPDRS Part II score, Mean (SD)	0.3 (0.9) *	2.3 (3.7)	2.1 (2.8)	<.0001 ^	<.0001 ^	0.6108
MDS-UPDRS Part III score, Mean (SD)	0.9 (1.4) *	4.4 (4.5) *	4.3 (4.9) *	<.0001 ^	<.0001 ^	0.9353
Benzodiazepine use, N (%)	5 (4%)	2 (2%)	4 (4%)	0.4639	0.7281	0.4356
Antidepressant use, N (%)	14 (10%)	17 (17%)	33 (34%)	0.0271	<.0001 ^	0.0047 ^
RBD treatment (yes), N (%)	7 (5%)	57 (56%)	67 (70%)	<.0001 ^	<.0001 ^	0.0524
BIOLOGIC CHARACTERISTICS						
DaTscan mean striatal SBR, Mean (SD)	2.69 (0.53) *	2.40 (0.44)	1.62 (0.28)	-	-	-
UPSIT (raw score), Mean (SD)	34.6 (3.8)	22.2 (6.7)	20.5 (6.8)	<.0001^	<.0001 ^	0.0619
Hyposmia (% ≤ 15th percentile), N (%)	8 (6%)	72 (71%)	75 (78%)	<.0001^	<.0001 ^	0.2703

* 2 DAT negative iRBD participants had missing race information, while 1 DAT positive iRBD participant and 5 DAT negative iRBD participants had missing ethnicity information. Duration since RBD diagnosis and duration since RBD symptom onset was missing for 4 DAT negative iRBD participants and 5 DAT positive iRBD participants. Site investigator cognitive diagnosis was not reported for robust HC group since it was missing for 85 participants and only 1 HC participant had MCI diagnosis. MDS UPDRS Part 1 Psychosis and Apathy scores were missing for 1 robust HC and 1DAT positive iRBD participant. MDS UPDRS Part II score was missing for 1 robust HC participant. MDS UPDRS Part III score was missing for 1 robust HC participant, 1 DAT negative iRBD participant and 2 DAT positive iRBD participants. Mean striatum variable was missing for 4 robust HC participants due to missing DATscan.

** Duration of self-reported time since RBD diagnosis in years.

*** Duration of self-reported time since onset of RBD symptoms in years.

**** Comparison between DAT negative and DAT positive groups was performed by using- t-test or Wilcoxon rank sum tests for continuous variables, and Chi-square or Fisher's exact test for categorical variables. Comparison between HC and DAT positive, HC and DAT negative groups was adjusted for age and sex and performed using linear and logistic regression models (except for age, sex, cognitive summary score and hyposmia (%<15th percentile))

^ The Benjamini & Hochberg method was used to control the false discovery rate at 5%. The upper BH boundary was 0.0237; therefore, all p-values less than 0.0237 are considered significant (indicated by '^' at the end of the p-value).

Table 3. Comorbid clinical symptoms of prodromal Lewy body disorder in iRBD with synucleinopathy

Variable	Definition	Overall iRBD NSD+ (*N*=197)
ESSENTIAL CRITERION		
iRBD with NSD	PSG-confirmed iRBD	197 (100%)
CORE CLINICAL FEATURES		
Mild Cognitive Impairment (MCI, %yes)	**MoCA ≤ 25**	**63 (32%)**
Subthreshold Parkinsonism (%yes)	**MDS-UPDRS Part III ≥ 5***	**53 (27%)**
Neuropsychiatric (%yes)	MDS-UPDRS Part I Psychosis 1.2 ≥ 1	13 (7%)
	MDS-UPDRS Part I Depression 1.3 ≥ 1	50 (26%)
	MDS-UPDRS Part I Anxiety 1.4 ≥ 1	70 (36%)
	MDS-UPDRS Part I Apathy 1.5 ≥ 1	41 (21%)
	Any Neuropsychiatric	**100 (51%)**
Autonomic (%yes)	MDS-UPDRS Part I Urinary Problems 1.10 ≥ 1	103 (52%)
	MDS-UPDRS Part I Lightheadedness 1.12 ≥ 1	79 (40%)
	MDS-UPDRS Part I Constipation 1.11 ≥ 1	96 (49%)
	Any Autonomic	**153 (78%)**
Sensory (%yes)	Hyposmia (% ≤ 15th percentile)	147 (75%)
	MDS-UPDRS Part I Pain 1.9 ≥ 1	107 (54%)
	Any Sensory	**173 (88%)**
PRODROMAL LEWY BODY DISORDER (%YES)	iRBD + 0 Core Features	3 (2%)
	iRBD + 1 Core Feature	21 (11%)
	iRBD + 2 Core Features	55 (28%)
	iRBD + 3 Core Features	71 (36%)
	iRBD + 4 Core Features	37 (19%)
	iRBD + 5 Core Features	10 (5%)

*Excluding postural and action tremor
**Neuropsychiatric features could not be evaluated for 1 participant due to missing MDS UPDRS items 1.2, 1.3, 1.4, 1.5

REFERENCES

1. Hu MT. REM sleep behavior disorder (RBD). *Neurobiol Dis*. Sep 2020;143:104996. doi:10.1016/j.nbd.2020.104996
2. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. *Neurology*. Jul 04 2017;89(1):88–100. doi:10.1212/WNL.0000000000004058
3. Chahine LM, Xie SX, Simuni T, et al. Longitudinal changes in cognition in early Parkinson's disease patients with REM sleep behavior disorder. *Parkinsonism Relat Disord*. Mar 12 2016;27:102–106. doi:10.1016/j.parkreldis.2016.03.006
4. Lin YQ, Chen SD. RBD: a red flag for cognitive impairment in Parkinson's disease? *Sleep Med*. Apr 2018;44:38–44. doi:10.1016/j.sleep.2018.01.006
5. Postuma RB, Iranzo A, Hu M, et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. *Brain*. Mar 1 2019;142(3):744–759. doi:10.1093/brain/awz030
6. Iranzo A, Fernandez-Arcos A, Tolosa E, et al. Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. *PLoS ONE*. 2014 2014;9:e89741. Not in File.
7. Berg D, Postuma RB, Adler CH, et al. MDS research criteria for prodromal Parkinson's disease. *Movement Disorders*. 2015 2015;30:1600–1611. Not in File.
8. Heinzel S, Berg D, Gasser T, et al. Update of the MDS research criteria for prodromal Parkinson's disease. *Mov Disord*. Aug 14 2019;34:1464–1470. doi:10.1002/mds.27802
9. McKeith IG, Ferman TJ, Thomas AJ, et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. *Neurology*. Apr 28 2020;94(17):743–755. doi:10.1212/WNL.0000000000009323
10. Gagnon JF, Vendette M, Postuma RB, et al. Mild cognitive impairment in rapid eye movement sleep behavior disorder and Parkinson's disease. *Ann Neurol*. Jul 2009;66(1):39–47. doi:10.1002/ana.21680
11. Arnaldi D, Chincarini A, De Carli F, et al. The fate of patients with REM sleep behavior disorder and mild cognitive impairment. *Sleep Med*. Mar 2021;79:205–210. doi:10.1016/j.sleep.2020.02.011
12. Joza S, Hu MT, Jung KY, et al. Prodromal dementia with Lewy bodies in REM sleep behavior disorder: A multicenter study. *Alzheimers Dement*. Jan 2024;20(1):91–102. doi:10.1002/alz.13386
13. Elasfar S, Hameed H, Ehgoetz Martens K. Motor features that distinguish isolated REM sleep behavior disorder patients from healthy controls: A systematic review. *J Parkinsons Dis*. Sep 1 2025:1877718X251359225. doi:10.1177/1877718X251359225
14. Gunawardana CW, Matar E, Lewis SJG. The clinical phenotype of psychiatric-onset prodromal dementia with Lewy bodies: a scoping review. *J Neurol*. Jan 2024;271(1):606–617. doi:10.1007/s00415-023-12000-w
15. Pearson J, Badenoch JB, Van Wamelen D. Using prodromal non-motor symptoms to predict Parkinson's disease onset and motor phenotype. *J Neurol Neurosurg Psychiatry*. Jun 19 2025;doi:10.1136/jnnp-2024-335429
16. Navarro-Otano J, Llanso L, Alejaldre A, Diez L, Santamaria J, Iranzo A. Autonomic nervous system dysfunction in idiopathic REM sleep behavior disorder as a short-term risk for a synucleinopathy. *J Neurol*. Dec 2 2024;272(1):1. doi:10.1007/s00415-024-12787-2
17. Ferini-Strambi L, Oertel W, Dauvilliers Y, et al. Autonomic symptoms in idiopathic REM behavior disorder: a multicentre case-control study. *J Neurol*. Jun 2014;261(6):1112–8. doi:10.1007/s00415-014-7317-8
18. Iranzo A, Marrero-Gonzalez P, Serradell M, Gaig C, Santamaria J, Vilaseca I. Significance of hyposmia in isolated REM sleep behavior disorder. *J Neurol*. Mar 2021;268(3):963–966. doi:10.1007/s00415-020-10229-3
19. van Duijvenboden S, Ramirez J, Scheurink J, et al. Heart rate profiles during exercise and incident Parkinson's disease. *Ann Neurol*. Aug 2 2025;doi:10.1002/ana.70010

20. Wang C, Chen F, Li Y, Liu J. Possible predictors of phenoconversion in isolated REM sleep behaviour disorder: a systematic review and meta-analysis. *J Neurol Neurosurg Psychiatry*. Apr 2022;93(4):395–403. doi:10.1136/jnnp-2021-328062
21. Siderowf A, Concha-Marambio L, Lafontant DE, et al. Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using alpha-synuclein seed amplification: a cross-sectional study. *Lancet Neurol*. May 2023;22(5):407–417. doi:10.1016/S1474-4422(23)00109-6
22. Liu R, Umbach DM, Troster AI, Huang X, Chen H. Non-motor symptoms and striatal dopamine transporter binding in early Parkinson's disease. *Parkinsonism Relat Disord*. Mar 2020;72:23–30. doi:10.1016/j.parkreldis.2020.02.001
23. Kim YE, Kim YJ, Hwang HS, Ma HI. REM sleep behavior disorder in early Parkinson's disease predicts the rapid dopaminergic denervation. *Parkinsonism Relat Disord*. Nov 2020;80:120–126. doi:10.1016/j.parkreldis.2020.09.032
24. Pereira JB, Weintraub D, Chahine L, Aarsland D, Hansson O, Westman E. Cortical thinning in patients with REM sleep behavior disorder is associated with clinical progression. *npj Parkinson's Disease*. 2019/05/03 2019;5(1):7. doi:10.1038/s41531-019-0079-3
25. Ye G, Li Y, Zhou L, et al. Predictors of conversion to alpha-synucleinopathy diseases in idiopathic rapid eye movement sleep behavior disorder. *J Parkinsons Dis*. 2020;10(4):1443–1455. doi:10.3233/JPD-202243
26. Marek K, Chowdhury S, Siderowf A, et al. The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort. *Ann Clin Transl Neurol*. Dec 2018;5(12):1460–1477. doi:10.1002/acn3.644
27. Weintraub D BM, Kurth R, York MY, and the Parkinson’s Progression Markers Initiative. Use of robust norming to create a sensitive cognitive summary score in de novo Parkinson’s disease: an illustrative example. *Movement Disorders*. 2025;40:468–477.
28. Weintraub D, Nair AR, Kurth R, et al. Cognitive performance in early neuronal synuclein disease with hyposmia but without motor disability: association with dopamine deficiency and isolated rapid eye movement sleep behavior disorder. *Ann Neurol*. Jul 11 2025;98:482–491. doi:10.1002/ana.27263
29. Simuni T, Chahine LM, Poston K, et al. A biological definition of neuronal alpha-synuclein disease: towards an integrated staging system for research. *Lancet Neurol*. Feb 2024;23(2):178–190. doi:10.1016/S1474-4422(23)00405-2
30. Dam T, Pagano G, Brumm MC, et al. Neuronal alpha-Synuclein Disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohorts. *NPJ Parkinsons Dis*. Sep 27 2024;10(1):178. doi:10.1038/s41531-024-00789-w
31. Caspell-Garcia C, Simuni T, Tosun-Turgut D, et al. Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. *PLoS One*. 2017;12(5):e0175674. doi:10.1371/journal.pone.0175674
32. Nasreddine Z, Phillips N, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *Journal of the American Geriatrics Society*. 2005 2005;53:695–699. In File.
33. Dalrymple-Alford J, MacAskill M, Nakas C, et al. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. *Neurology*. 2010 2010;75(19):1717–1725. Not in File.
34. Sheikh J, Yesavage J. Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. In: TL B, ed. *Clinical Gerontology: A Guide to Assessment and Intervention*. The Haworth Press; 1986:165–173.
35. Spielberger C, Gorsuch R, Lushene R, Vagg P, Jacobs G. *Manual for the State-Trait Anxiety Inventory (Form Y)*. Consulting Psychologists Press; 1983.
36. Doty R, Shaman P, Dann M. Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. *Physiology and Behavior*. 1984 1984;32:489–502. Not in File.
37. Brumm MC, Pierz KA, Lafontant DE, et al. Updated percentiles for the University of Pennsylvania Smell Identification Test in adults 50 years of age and older. *Neurology*. Apr 18 2023;100(16):e1691–e1701. doi:10.1212/WNL.0000000000207077

38. Pierz KA, Aamodt W, Gochanour C, et al. Percentile scores for the revised University of Pennsylvania Smell Identification Test for 16,972 individuals 60 years of age and older. *NPJ Parkinsons Dis*. Oct 1 2025;11(1):280. doi:10.1038/s41531-025-01095-9
39. Kim R, Jin B, Kim H, et al. Cholinergic basal forebrain degeneration in isolated REM sleep behaviour disorder. *Brain*. May 26 2025;doi:10.1093/brain/awaf196
40. Knudsen K, Fedorova TD, Hansen AK, et al. In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study. *Lancet Neurol*. Jul 2018;17(7):618–628. doi:10.1016/S1474-4422(18)30162-5
41. Ray Chaudhuri K, Leta V, Bannister K, Brooks DJ, Svenningsson P. The noradrenergic subtype of Parkinson disease: from animal models to clinical practice. *Nat Rev Neurol*. Jun 2023;19(6):333–345. doi:10.1038/s41582-023-00802-5
42. Maya G, Iranzo A, Gaig C, et al. Post-mortem neuropathology of idiopathic rapid eye movement sleep behaviour disorder: a case series. *Lancet Neurol*. Dec 2024;23(12):1238–1251. doi:10.1016/S1474-4422(24)00402-2
43. Weintraub D, Newberg A, Cary M, et al. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease. *Journal of Nuclear Medicine*. 2005 2005;46:227–232. PMCID: PMC15695780. Not in File.
44. Schrag A, Horsfall L, Walters K, Noyce A, Petersen I. Prediagnostic presentations of Parkinson's disease in primary care: a case-control study. *Lancet Neurol*. 2015 2015;14:57–64. Not in File.
45. Leentjens AF, Van den Akker M, Metsemakers JF, Lousberg R, Verhey FR. Higher incidence of depression preceding the onset of Parkinson's disease: a register study. *Mov Disord*. Apr 2003;18(4):414–8. doi:10.1002/mds.10387
46. Pauly L, Rauschenberger A, Pauly C, et al. Cognition and other non-motor symptoms in an at-risk cohort for Parkinson's disease defined by REM-sleep behavior disorder and hyposmia. *J Parkinsons Dis*. 2024;14(3):545–556. doi:10.3233/JPD-230285
47. Honeycutt L, Gagnon JF, Pelletier A, Montplaisir JY, Gagnon G, Postuma RB. Characterization of depressive and anxiety symptoms in idiopathic REM sleep behavior disorder. *J Parkinsons Dis*. 2021;11(3):1409–1416. doi:10.3233/JPD-212625
48. Postuma RB, Gagnon JF, Vendette M, Montplaisir JY. Markers of neurodegeneration in idiopathic rapid eye movement sleep behaviour disorder and Parkinson's disease. *Brain*. Dec 2009;132(Pt 12):3298–307. doi:10.1093/brain/awp244
49. Iranzo A, Tolosa E, Gelpi E, et al. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. *Lancet Neurol*. May 2013;12(5):443–53. doi:10.1016/S1474-4422(13)70056-5
50. Postuma R, Gagnon J-F, Bertrand J-A, Genier D, Montplaisir J. Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. *Neurology*. 2015 2015;84:1–10. Not in File.
51. Elliott JE, Lim MM, Keil AT, et al. Baseline characteristics of the North American prodromal Synucleinopathy cohort. *Ann Clin Transl Neurol*. Apr 2023;10(4):520–535. doi:10.1002/acn3.51738

Figure 1. Bar graphs of frequency of comorbid clinical domains in iRBD using original criteria



Figure 2. UpSet plot of overlap of comorbid clinical features